NASDAQ:AURA

Aura Biosciences (AURA) Stock Price, News & Analysis

Aura Biosciences logo
$6.87 -0.11 (-1.58%)
Closing price 03:58 PM Eastern
Extended Trading
$6.88 +0.01 (+0.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Aura Biosciences Stock (NASDAQ:AURA)

Advanced

Key Stats

Today's Range
$6.51
▼
$6.98
50-Day Range
$6.00
▼
$7.66
52-Week Range
$4.73
▼
$9.53
Volume
791,133 shs
Average Volume
814,890 shs
Market Capitalization
$714.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50
Consensus Rating
Moderate Buy

Company Overview

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area.

Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

Aura is also exploring its technology for other ocular and solid tumors. Its programs remain under clinical development, and belzupacap sarotalocan is not an approved treatment.

AI Generated. May Contain Errors.

Aura Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

AURA MarketRank™: 
1.829939460645 of 5 stars

Aura Biosciences scored higher than 37% of companies evaluated by MarketBeat, and ranked 670th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aura Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Aura Biosciences has a consensus price target of $17.50, representing about 154.7% upside from its current price of $6.87.

  • Amount of Analyst Coverage

    Aura Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aura Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Aura Biosciences are expected to grow in the coming year, from ($1.48) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aura Biosciences is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aura Biosciences is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aura Biosciences has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.29% of the float of Aura Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Aura Biosciences has a short interest ratio ("days to cover") of 13.67, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Aura Biosciences has recently decreased by 3.87%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aura Biosciences does not currently pay a dividend.

  • Dividend Growth

    Aura Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Aura Biosciences has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Aura Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aura Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.90% of the stock of Aura Biosciences is held by insiders.

  • Percentage Held by Institutions

    96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aura Biosciences' insider trading history.
Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AURA Stock News Headlines

Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
See More Headlines

AURA Stock Analysis - Frequently Asked Questions

Aura Biosciences' stock was trading at $5.45 at the beginning of the year. Since then, AURA shares have increased by 26.1% and is now trading at $6.87.

Aura Biosciences, Inc. (NASDAQ:AURA) released its earnings results on Monday, November, 9th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08.

Aura Biosciences (AURA) raised $81 million in an initial public offering on Thursday, October 28th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share.

Top institutional shareholders of Aura Biosciences include Nantahala Capital Management LLC (3.66%), State Street Corp (2.21%), Bellevue Group AG (1.36%) and Goldman Sachs Group Inc. (0.91%). Insiders that own company stock include Los Pinos Elisabet De, Anthony S Gibney, Janet Jill Hopkins, Conor Kilroy, Mark Plavsic, David Michael Johnson, Julie B Feder, Amy Elazzouzi and Matrix Capital Management Comp.
View institutional ownership trends
.

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aura Biosciences investors own include Micron Technology (MU), Palantir Technologies (PLTR), SoFi Technologies (SOFI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Applied Digital (APLD) and Aurora Innovation (AUR).

Company Calendar

Last Earnings
11/09/2026
Today
11/20/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Investor update
12/08/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AURA
CIK
1501796
Fax
N/A
Employees
113
Year Founded
2009

Price Target and Rating

High Price Target
$18.00
Low Price Target
$17.00
Potential Upside/Downside
+154.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$106.19 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-64.68%
Return on Assets
-56.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.20
Quick Ratio
14.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.76 per share
Price / Book
2.49

Miscellaneous

Outstanding Shares
104,070,000
Free Float
102,097,000
Market Cap
$714.96 million
Optionable
Optionable
Beta
0.41

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:AURA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners